Vimarsana
Biggest News Aggregation in the World

Page 4 - Inflammatory Disorders News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inflammatory Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inflammatory Disorders Today - Breaking & Trending Today

Tezspire™ (tezepelumab injection) now available in Canada for severe asthma - Vimarsana News

Tezspire™ (tezepelumab injection) now available in Canada for severe asthma

/CNW/ - Today, AstraZeneca and Amgen announced the Canadian availability of Tezspire™ (tezepelumab injection), indicated for the add-on maintenance treatment...

How Multimodal Imaging Helps Differentiate Between Mechanisms of Outer Retinal Damage - Vimarsana News

How Multimodal Imaging Helps Differentiate Between Mechanisms of Outer Retinal Damage

A recent study published in Diagnostics identifies multimodal imaging traits to distinguish primary inflammatory choriocapillaropathies, such as multiple evanescent white dot syndrome and idiopathic multifocal choroiditis, from primary photoreceptoritis.

First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations - Vimarsana News

First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations

AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The ...

Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma - Vimarsana News

Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations. AstraZeneca's Tezspire has been recommended for marketing authorisation... | July 25, 2022

NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS - Vimarsana News

NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...